An interventional study of CoreDISTParticipation in Multiple Sclerosis, sponsored by Nordlandssykehuset HF. Active, not recruiting at 1 site in Norway. Open to participants aged 18 Years to 67 Years. Per ClinicalTrials.gov, last updated 2024-11-21.
Sponsored by Nordlandssykehuset HF · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 56 studies in Multiple Sclerosis with a site in Norway — 2 open to participants now, 9 under way, 3 of them phase 3. Multiple Sclerosis · Norway.
Among the 56 studies in Multiple Sclerosis with a site in Norway, this one is the 31st largest by planned enrollment of the 43 interventional ones that give a count, is the only one that started in 2024, is one of 9 with no phase, and was the 53rd registered.
3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →2 of the 56 studies in Multiple Sclerosis with a site in Norway are open now. Recruiting first, the newest first:
Oslo University Hospital · Sites in Norway
Ages 50–80
Haukeland University Hospital · Sites in Norway
Ages 18–65
A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →
Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.
This study: 18 Years to 67 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
56 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 10 · Phase 3 17 · Phase 4 6
First in 2002; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 114 is above the median of 50 across 2,208 interventional studies indexed under Multiple Sclerosis.
Median enrollment 300 across the 43 interventional studies, 599 across the 13 observational. Of the 41 that completed or were terminated, 20 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 56 have an industry lead sponsor. The 10 most frequent:
Nordlandssykehuset HF is the lead sponsor of 21 studies on the registry; 3 are open to participants now.
Nordlandssykehuset HF has 4 studies filed under Multiple Sclerosis — fewer than ten, so there is no comparison to draw.
1 of the studies in Multiple Sclerosis with a site in Norway that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05740722Haukeland University HospitalNicotinamide Riboside Supplementation In Progressive Multiple Sclerosis | 2027-08-01 |
Add it to your calendar (.ics) → With an account.
Among the 56 studies in Multiple Sclerosis with a site in Norway, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Employment is low in people with MS, even when physical levels of functioning are high. The purpose of this study is to investigate if an individually tailored intervention combining individualized physiotherapy and work adaptation works better than usual care in terms of reducing barriers for work and improving levels of physical activity. The utility of the intervention will be investigated in terms of quality adjusted life years, long-term employment status and work-related costs.
Physiotherapy and physical activity interventions can reduce fatigue, improve balance, walking, HRQoL, and may improve neuromuscular and physical functioning in people with MS. However, these interventions lack coordination between health care levels and sectors and rarely address vital employment adaptations. Optimizing function and physical activity, when disability is low and neuroplasticity is optimal, can be valuable for maintaining work as levels of fatigue, mobility related symptoms and cognitive disturbances are associated with current employment.
People with an MS-diagnosis who reside in the North of Norway will be identified from patient lists from the neurological out-patient clinics in the participating hospitals. Upon the provision of written informed consent, all participants will undergo baseline testing prior to randomization into either the intervention or the control group. The intervention group will receive a physiotherapy assessment at the hospitals focusing on opportunities for change. Following this assessment they will participate in group training with a municipality physiotherapist twice weekly for six weeks followed by independent training for six weeks. In addition, both participants and their employers will get access to information films on opportunities for work adaptations and the importance of physical activity. Structured meetings with a specially trained employment consultant, the participant and their employer will be held to discuss possible work adaptations. Goals will be set and formally evaluated. Retests will be carried out at week 9, 16 and 52. Registry data on employment will be obtained from the Norwegian labour and welfare administration as a part of a cost-benefit analysis of the intervention.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Week 1-2: a)Videos for PwMS and employers on MS, possible work adaptations, physical activity (PA) and function. b)A meeting between PwMS and a work-consultant (WC). They will decide if the PwMS should discuss the work situation with their employer or if the WC and/or other professionals are needed. c)A clinical assessment with a trained MS-OP-PT to explore possibilities for optimalisation of movement. Week 3-8: a)A clinical assessment with the mPT building on previous assessment. Goal-setting for function and PA. b)CoreDIST-training in groups, 6 weeks, 1/week. indoors and 1/week outdoors. Independent training 1/week, CoreDISTvideos. c)A follow up meeting regarding work, evaluation of goals with mPT. New goal setting for week 10-15 Week 10-15, Self-administered, digitally supported home training: a)CoreDIST-videos 3x10 min/week b)Training of own choice including elements of high intensity and balance 2x30 minutes per week. c)Week 15: Evaluation of goals regarding work and PA
Other: CoreDISTParticipation
Usual care (control group): These participants will continue with their regular routines and will be encouraged to obtain the national and MS-specific recommendation of 150-300 minutes of moderate physical activity or 75 minutes of high intensity physical activity per week or a combination of these, stay employed, continue medical treatment and seek any health care required, including physiotherapy.
CoreDISTparticipation is a multi-disciplinary individualized intervention that concurrently combine 1) providing PwMS and their employers with information on MS, possibilities for work-adaptations within the welfare system and the importance of physical activity 2) Structured goal-setting regarding reducing barriers for work and regarding physical function and activity for PwMS 3) A physiotherapy intervention focusing on improving the underlying prerequisites for balance and walking along with high intensive training and promotion of physical activity 4) structured evaluation and adjustment of goals.
Multiple Sclerosis Work Difficulties Questionnaire -23 Norwegian version
How frequently individuals with MS perceive psychological/cognitive (11 items), physical (8 items), external, (4 items) barriers related to work, scored by a 5-point scale (0=best).
Time frame: Baseline, 9, 16 and 52 weeks post baseline
Levels of physical activity measured using ActiGraph wGT3x-BT monitors
% of time in mild, moderate, intensive physical activity and sedate time
Time frame: Participants will wear device for one week after testing at baseline and at 9, 16 and 52 weeks post baseline
6 meter walk test
Walking distance (meters) within six minutes
Time frame: Baseline, 9, 16 and 52 weeks post baseline
Step count using ActiGraph wGT3x-BT monitors
Daily average number of steps
Time frame: Participants will wear device for one week after testing at baseline and at 9, 16 and 52 weeks post baseline
Fatigue Severity Scale -Norwegian version
Self-report, 9 items: physical, social and cognitive effects of fatigue, scale:1-7 (high score indicates higher levels of fatigue).
Time frame: Baseline, 9, 16 and 52 weeks post baseline
Multiple Sclerosis Walking Scale-12
Self-reported perception of walking, 12 items, score on a 5-point scale. Higher score indicate higher impact of MS on the individuals walking ability.
Time frame: Baseline, 9, 16 and 52 weeks post baseline
Mini Balance Evaluation Systems Test (MiniBESTest)
Pro-and reactive balance, dual task and involving sit to stand, standing and walking, 14 items on a 3-point scale. Higher score indicate better performance.
Time frame: Baseline, 9, 16 and 52 weeks post baseline
Trunk Impairment Scale-modified Norwegian version (TISmodNV)
Trunk control in sitting. 6 items, score on a 2- or 3-point scale, sum range 0-16 points. Higher score indicates higher levels of trunk control.
Time frame: Baseline, 9, 16 and 52 weeks post baseline
Postural control measured by AccuGait Optimized force platforms
Measures postural control in standing, tandem, one-leg standing: postural sway of center of pressure.
Time frame: Baseline, 9, 16 and 52 weeks post baseline
European Quality of Life 5-Dimension (EQ-5D-5L) + Complementary questions
Self-perceived HRQoL regarding five domains, and a VAS scale (0-100) on overall health. Complementary questions on sleep, wellbeing, emotions, social relations (advocated by the Norwegian Health Institute). Higher score indicate better self-perveived health.
Time frame: Baseline, 9, 16 and 52 weeks post baseline
Multiple Sclerosis Impact Scale 29-Norwegian version
Self-perceived physical (13 items), psychological (9 items) impact on HRQoL, a 5-point scale. Higher score indicate increased impact of MS on the individuals day-to-day life.
Time frame: Baseline, 9, 16 and 52 weeks post baseline
Patient Global Impression of Change - physical activity and balance
A global index that is used to rate the response of a condition to a therapy (transition scale). Higher score indicate improvement.
Time frame: Baseline, 9, 16 and 52 weeks post baseline
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2024 (actual). Primary completion is estimated for Dec 2024, 9 months after the start.
Of 852 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's planned 9 months is below that.
Counting every sponsor, half of 874 studies reached it within 21 months; a quarter within 9 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nordlandssykehuset HF